Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

s, cancer and potentially other therapeutic areas of interest to AstraZeneca."

"Regulus is pleased to form another significant strategic alliance on microRNA therapeutics," said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics Inc. "AstraZeneca is a global, innovation-driven company that we believe can greatly aid our efforts to advance microRNA therapeutics to the clinic and the market. The entire field of RNA therapeutics has been rapidly advancing, reaching significant milestones recently. We are committed to realize the broad utility of these new RNA-based medicines to treat human disease in the future. "

Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics Inc., added, "We wanted to partner our microRNA-33 program with AstraZeneca due to their excellent track record on developing and commercializing drugs in cardiovascular and metabolic diseases and their commitment to the RNA therapeutic field.  We look forward to growing our strategic relationship with AstraZeneca with additional targets to develop important first-in-class medicines."

About microRNA-33 for Atherosclerosis

Atherosclerosis is the build-up of plaque that occurs when cholesterol and inflammatory cells accumulate in blood vessels. These plaques can rupture, leading to slowing or blockage of blood flow and ultimately resulting in a heart attack or stroke. Scientific research has shown a strong correlation between high cholesterol levels and cardiovascular disease which, according to the Centers for Disease Control, is the leading cause of death in the United States.

Regulus' lead program for atherosclerosis targets microRNA-33, which has a unique mechanism of action for the management of cholesterol levels. The inhibition of microRNA-33 with our anti-miRs promotes reverse cholesterol transport, or RCT, which is the efflux of cholesterol from specific cholesterol-laden inflammatory cells calle
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Astellas ... director of Business Communications & Advocacy, Urology in ... Business Communications & Advocacy Margaret Long. In this role, ... to urology to patient and advocacy organizations, as ... on key strategic initiatives. Noland,s appointment is the ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
(Date:9/16/2014)... 16, 2014 /PRNewswire-iReach/ -- Dan York has ... manufacturer of the RTD ® Advanced Wound Care ... its sales presence in the U.S. Under York,s leadership, ... direct field sales representatives in new sales territories that ... to add up to 20 sales representatives in major ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... June 2 Today In the Face of ... help pain management advocates expand their outreach efforts through popular ... to social media applications, such as Facebook, and walks users ... communication vehicles. Topics include "An Overview of Social Media," "Advocacy ...
... , JERUSALEM , June ... of oral drug delivery systems, announced,today that its subsidiary Oramed ... Ltd. ("Laser Detect"), an Israeli company listed on,the Tel Aviv ... be,called Entera Bio Ltd. ("Entera"). Under the terms of the ...
Cached Medicine Technology:In the Face of Pain® Offers Social Media 101 for Pain Management Advocates 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Spring, Md. (PRWEB) September 16, 2014 Pulmonary ... Road , Free Education Forum for PH Patients and Families ... Pulmonary Hypertension Association – the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
(Date:9/16/2014)... 17, 2014 Today, Top10BestSEOHosting.com ... from the USA and announces that HostMonster, ... the best Windows web hosting companies in ... worldwide clients high quality WordPress hosting (including ... , HostMonster provides outstanding customer support ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... routinely spot human papillomavirus (HPV), which is linked to the ... study shows that testing urine for HPV has good accuracy ... HPV," said lead researcher Dr. Neha Pathak. She is a ... Mary University of London, England. The test could be ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... today at 10:00 a.m. EST by calling, ... the Web at: http://www.airproducts.com/Invest/financialnews/EarningsReleases.htm ... Products,(NYSE: APD ) today reported net income of ... for its fiscal first quarter ended December 31,2007. Net ...
... DEERFIELD, Ill., Jan. 23 Astellas Pharma Inc. ... (FDA) has approved their,Supplemental New Drug Application (sNDA) ... for Injection in the treatment of patients,with Candidemia, ... approved in 2005 for the treatment of patients ...
... NDA Approval for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), ... for the Prevention ... Preterm Birth in Singleton Pregnancies, ST. LOUIS, Jan. ... specialty pharmaceutical company that,develops, manufactures, acquires and markets technology-differentiated,branded ...
... Advanced Therapy, HOLLYWOOD, Fla., Jan. 22 ... clot-busting drugs may succeed with more,advanced therapies that ... data being presented at the 20th annual International ... fail to improve with standard intravenous (IV),stroke therapy ...
... Calif., Jan. 22 Coherent, Inc.,(Pink Sheets: COHR), today ... market close and host a live webcast to discuss,its ... 7,2008 at 4:30 p.m. ET., The call will ... accessed,at either http://www.coherent.com/Investors/ or http://www.earnings.com .,For ...
... boy,s body is taken to the cleaners with the hospital ... Worth,couple has filed a lawsuit against Huguley Memorial Medical Center ... cleaners with the,hospital laundry., On July 8, 2007, Kourtney ... did not survive and his body was taken to the,hospital ...
Cached Medicine News:Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 2Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 3Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 4Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 5Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 6Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 7Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 8Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 9Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 10Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 11Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 12Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 13Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 14Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 15Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 16Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 2Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5Health News:Stroke Undertreated 2Health News:Stroke Undertreated 3Health News:A Fort Worth Couple Sues Huguley Memorial Medical Center 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: